Cost-effectiveness of HBV and HCV screening strategies: a systematic review of existing modelling techniques

Claudia Geue, Olivia Wu, Yiqiao Xin, Robert Heggie, Sharon Hutchinson, Natasha K. Martin, Elisabeth Fenwick, David Goldberg

Research output: Contribution to journalArticle

25 Downloads (Pure)

Abstract

Introduction
Studies evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are generally heterogeneous in terms of risk groups, settings, screening intervention, outcomes and the economic modelling framework. It is therefore difficult to compare cost-effectiveness results between studies. This systematic review aims to summarise and critically assess existing economic models for HBV and HCV in order to identify the main methodological differences in modelling approaches.

Methods
A structured search strategy was developed and a systematic review carried out. A critical assessment of the decision-analytic models was carried out according to the guidelines and framework developed for assessment of decision-analytic models in Health Technology Assessment of health care interventions.

Results
The overall approach to analysing the cost-effectiveness of screening strategies was found to be broadly consistent for HBV and HCV. However, modelling parameters and related structure differed between models, producing different results. More recent publications performed better against a performance matrix, evaluating model components and methodology.

Conclusion
When assessing screening strategies for HBV and HCV infection, the focus should be on more recent studies, which applied the latest treatment regimes, test methods and had better and more complete data on which to base their models. In addition to parameter selection and associated assumptions, careful consideration of dynamic versus static modelling is recommended. Future research may want to focus on these methodological issues. In addition, the ability to evaluate screening strategies for multiple infectious diseases, (HCV and HIV at the same time) might prove important for decision makers.
Original languageEnglish
Article numbere0145022
Number of pages27
JournalPLoS ONE
Volume10
Issue number12
DOIs
Publication statusPublished - 21 Dec 2015

Fingerprint

Hepatitis C virus
Hepatitis B virus
systematic review
cost effectiveness
Cost effectiveness
Viruses
Hepacivirus
Cost-Benefit Analysis
Screening
screening
Economic Models
Biomedical Technology Assessment
methodology
Hepatitis A
Virus Diseases
Communicable Diseases
Economics
HIV
Guidelines
Delivery of Health Care

Keywords

  • HCV screening
  • screening guidelines
  • cost-effectiveness
  • Markov models

Cite this

Geue, Claudia ; Wu, Olivia ; Xin, Yiqiao ; Heggie, Robert ; Hutchinson, Sharon ; Martin, Natasha K. ; Fenwick, Elisabeth ; Goldberg, David. / Cost-effectiveness of HBV and HCV screening strategies : a systematic review of existing modelling techniques. In: PLoS ONE . 2015 ; Vol. 10, No. 12.
@article{23dd5b8f230b4f8c82353a21246997d6,
title = "Cost-effectiveness of HBV and HCV screening strategies: a systematic review of existing modelling techniques",
abstract = "IntroductionStudies evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are generally heterogeneous in terms of risk groups, settings, screening intervention, outcomes and the economic modelling framework. It is therefore difficult to compare cost-effectiveness results between studies. This systematic review aims to summarise and critically assess existing economic models for HBV and HCV in order to identify the main methodological differences in modelling approaches.MethodsA structured search strategy was developed and a systematic review carried out. A critical assessment of the decision-analytic models was carried out according to the guidelines and framework developed for assessment of decision-analytic models in Health Technology Assessment of health care interventions.ResultsThe overall approach to analysing the cost-effectiveness of screening strategies was found to be broadly consistent for HBV and HCV. However, modelling parameters and related structure differed between models, producing different results. More recent publications performed better against a performance matrix, evaluating model components and methodology.ConclusionWhen assessing screening strategies for HBV and HCV infection, the focus should be on more recent studies, which applied the latest treatment regimes, test methods and had better and more complete data on which to base their models. In addition to parameter selection and associated assumptions, careful consideration of dynamic versus static modelling is recommended. Future research may want to focus on these methodological issues. In addition, the ability to evaluate screening strategies for multiple infectious diseases, (HCV and HIV at the same time) might prove important for decision makers.",
keywords = "HCV screening, screening guidelines, cost-effectiveness, Markov models",
author = "Claudia Geue and Olivia Wu and Yiqiao Xin and Robert Heggie and Sharon Hutchinson and Martin, {Natasha K.} and Elisabeth Fenwick and David Goldberg",
year = "2015",
month = "12",
day = "21",
doi = "10.1371/journal.pone.0145022",
language = "English",
volume = "10",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "PLOS",
number = "12",

}

Cost-effectiveness of HBV and HCV screening strategies : a systematic review of existing modelling techniques. / Geue, Claudia; Wu, Olivia; Xin, Yiqiao; Heggie, Robert; Hutchinson, Sharon; Martin, Natasha K.; Fenwick, Elisabeth; Goldberg, David.

In: PLoS ONE , Vol. 10, No. 12, e0145022, 21.12.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-effectiveness of HBV and HCV screening strategies

T2 - a systematic review of existing modelling techniques

AU - Geue, Claudia

AU - Wu, Olivia

AU - Xin, Yiqiao

AU - Heggie, Robert

AU - Hutchinson, Sharon

AU - Martin, Natasha K.

AU - Fenwick, Elisabeth

AU - Goldberg, David

PY - 2015/12/21

Y1 - 2015/12/21

N2 - IntroductionStudies evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are generally heterogeneous in terms of risk groups, settings, screening intervention, outcomes and the economic modelling framework. It is therefore difficult to compare cost-effectiveness results between studies. This systematic review aims to summarise and critically assess existing economic models for HBV and HCV in order to identify the main methodological differences in modelling approaches.MethodsA structured search strategy was developed and a systematic review carried out. A critical assessment of the decision-analytic models was carried out according to the guidelines and framework developed for assessment of decision-analytic models in Health Technology Assessment of health care interventions.ResultsThe overall approach to analysing the cost-effectiveness of screening strategies was found to be broadly consistent for HBV and HCV. However, modelling parameters and related structure differed between models, producing different results. More recent publications performed better against a performance matrix, evaluating model components and methodology.ConclusionWhen assessing screening strategies for HBV and HCV infection, the focus should be on more recent studies, which applied the latest treatment regimes, test methods and had better and more complete data on which to base their models. In addition to parameter selection and associated assumptions, careful consideration of dynamic versus static modelling is recommended. Future research may want to focus on these methodological issues. In addition, the ability to evaluate screening strategies for multiple infectious diseases, (HCV and HIV at the same time) might prove important for decision makers.

AB - IntroductionStudies evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are generally heterogeneous in terms of risk groups, settings, screening intervention, outcomes and the economic modelling framework. It is therefore difficult to compare cost-effectiveness results between studies. This systematic review aims to summarise and critically assess existing economic models for HBV and HCV in order to identify the main methodological differences in modelling approaches.MethodsA structured search strategy was developed and a systematic review carried out. A critical assessment of the decision-analytic models was carried out according to the guidelines and framework developed for assessment of decision-analytic models in Health Technology Assessment of health care interventions.ResultsThe overall approach to analysing the cost-effectiveness of screening strategies was found to be broadly consistent for HBV and HCV. However, modelling parameters and related structure differed between models, producing different results. More recent publications performed better against a performance matrix, evaluating model components and methodology.ConclusionWhen assessing screening strategies for HBV and HCV infection, the focus should be on more recent studies, which applied the latest treatment regimes, test methods and had better and more complete data on which to base their models. In addition to parameter selection and associated assumptions, careful consideration of dynamic versus static modelling is recommended. Future research may want to focus on these methodological issues. In addition, the ability to evaluate screening strategies for multiple infectious diseases, (HCV and HIV at the same time) might prove important for decision makers.

KW - HCV screening

KW - screening guidelines

KW - cost-effectiveness

KW - Markov models

U2 - 10.1371/journal.pone.0145022

DO - 10.1371/journal.pone.0145022

M3 - Article

VL - 10

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 12

M1 - e0145022

ER -